NBB, that thought has been in my mind for a few weeks but I was holding off on expressing it on the forum. I just re-read the AGM transcript and while it is full of exciting scientific findings (tidbits) there are many issues to be addressed such as why some patients seem to benefit while others don't, why if the CURATE:AI approach proved that zen3694 modulates PSA why would Don not fund replication in other patients to build the case with companies like Pfizer, why did Don refer to a another deal in China like Hepalink when J & J and Pfizer would be the natural targets, etc?

I certainly don't blame Don for being excited. I'm excited because, as he points out, this is an enitrely new business model i.e. possibly working with multiple drug makers and making them millions of $. However, Don did not demonstrate to me that he has the business case buttoned down. His presentation was not tight from a business perspective and given that we are now over 2 months from the Sept 11 AGM with no visible action I'm feeling that Don just wanted to paint a rosy picture because he had to face shareholders. Now he has a 10 month break until the next confrontation and who knows what will happen.

I really hope I am wrong but I've been around 10 years. A Hepalink style deal seems plausable because the Chinese are very focused and strategic on this area and it's intellectual properties. Keep in mind there is that other Hepalink capital company based in Shenzhen that holds a sizable chunk of RVX.

Even if a deal happens I haven't seen any concrete indication it will benefit Zenith shareholders. My sense is that this is promising science but there is still a lot of science to be done just on zen3694.

However, there may well be a suitor willing to pick up this ball and carry it forward.

I'm always hopeful but Don tends to undermine my confidence. He has been successful at acquiring funds but to my knowledge has has not been able to use assets like the blood bank to generate and revenue as has has mentioned in numerous presentations.

Obviously these are just my opinions. I've begun to believe the BPs are very conservative and are not likely to take a crap shoot on a some early science and a business case that is not even put together in terms of what I have seen.

GLTA

Toinv